about
Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future PerspectivesTGF-β2-mediated ocular hypertension is attenuated in SPARC-null mice.Neuroprotection and progenitor cell renewal in the injured adult murine retina requires healing monocyte-derived macrophages.Rationale for the use of multifunctional drugs as neuroprotective agents for glaucoma.TRPC6: an underlying target for human glaucomaClosed gateways--can neuroprotectants shield the retina in glaucoma?Regulation of SPARC by transforming growth factor β2 in human trabecular meshworkOverexpression of SPARC in human trabecular meshwork increases intraocular pressure and alters extracellular matrixNeuroprotection in glaucoma: drug-based approaches.The papilla as screening parameter for early diagnosis of glaucomaThe East London glaucoma prediction score: web-based validation of glaucoma risk screening toolPresent and New Treatment Strategies in the Management of Glaucoma.Effect of Anti-vascular Endothelial Growth Factor Antibody on the Survival of Cultured Retinal Ganglion Cells.Human Pluripotent Stem Cell-Derived Retinal Ganglion Cells: Applications for the Study and Treatment of Optic Neuropathies.A validated stability-indicating HPLC method for determination of brimonidine tartrate in BRI/PHEMA drug delivery systems.Histological, morphometric, protein and gene expression analyses of rat retinas with ischaemia-reperfusion injury model treated with sildenafil citrate.Glaucoma in Patients with Eyes Close to Areas Affected by Port-wine Stain has Lateral and Gender Predilection.
P2860
Q26775083-F497B955-8743-42EB-BE93-C60E9BB44424Q33835663-D191C09F-C1FA-4010-B87A-B22544C3AB6AQ34501419-C794F18E-039B-4C41-8329-13355840321AQ35157723-7A427EB3-A59D-4DDF-B50E-41E9171DAE06Q36192203-FCEE1ED8-C3B8-499E-B1C5-7E2254D8ABF9Q36648977-C0B84B95-B23D-4636-BF49-A15EB2213EBEQ36765850-EB73855E-3E2F-49C3-B177-F5EBE66E4F07Q36827557-4DC7BB6C-E566-458E-8FBE-18E0690D1400Q37180770-643B2FF4-B76E-4E04-BB16-2A227E5783DBQ37188085-4602D8C8-4207-493A-9904-F0D5115B7756Q38095426-D61E9A1D-FA43-4094-A1DB-58859097BFC2Q38526185-03FF1C3F-0F7C-40B6-9CEC-CCD4E911275CQ41221841-93D21DF6-A4EE-42A2-89EF-30E28BB5CFB4Q42099855-A722C372-C659-481D-9A4B-A91B567BD778Q42943888-ECE80068-0311-4C5B-AA4E-71EFA6A6B01DQ47889918-1E39BFE6-2AA4-49CF-9278-6BEF5D8C031AQ49194345-96D7277B-DA32-46BF-8FC6-FD21C5CB22BE
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Glaucoma neuroprotection: What is it? Why is it needed?
@en
type
label
Glaucoma neuroprotection: What is it? Why is it needed?
@en
prefLabel
Glaucoma neuroprotection: What is it? Why is it needed?
@en
P1476
Glaucoma neuroprotection: What is it? Why is it needed?
@en
P304
P356
10.3129/CAN.J.OPHTHALMOL.I07-045
P577
2007-06-01T00:00:00Z